Physician profile
Brandon Hansen
NPI 1467735621
$10,159.64
in general payments reported to CMS, 2019-2025
59 companies · $2,386 in 2025
The $2,386 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,865 · 2022: $2,023 · 2023: $1,808 · 2024: $2,077 · 2025: $2,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,271.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,536.73 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $705.89 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $684.26 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.09 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Novo Nordisk INC | $431.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $392.15 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $384.39 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Supernus Pharmaceuticals, INC. | $356.27 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $337.37 | 2021-2025 | Vyepti, Rexulti |
| Pfizer INC. | $324.78 | 2021-2025 | |
| Corcept Therapeutics | $288.12 | 2024-2025 | Korlym |
| Corium, LLC | $237.74 | 2022-2024 | Azstarys |
| Tris Pharma INC | $226.03 | 2022-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $206.33 | 2022-2024 | |
| Tersera Therapeutics LLC | $194.77 | 2024-2025 | Quzyttir |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.